New treatment strategy of refractory prostate cancer by targeting interdependent signaling pathways.

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K20109
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Keio University
• Principal Investigator: Hongo Hiroshi 慶應義塾大学, 医学部(信濃町), 特任助教 (10626675)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 去勢抵抗性前立腺癌 / ドセタキセル耐性 / 相互依存的シグナル / アンドロゲン受容体

Outline of Final Research Achievements

We evaluated the therapeutic potential of targeting STAT5 signaling. We used two human prostate cancer cell lines: LNCaP, a androgen-dependent prostate cancer cell line; and C4-2AT6, a castration-resistant prostate cancer cell line. C4-2AT6 had docetaxel resistance. Western blotting showed higher expression of pAKT and pSTAT5 in C4-2AT6. We identified a novel stat5 inhibitor, ME001. ME001 had anti-tumor effect for C4-2AT6 in vitro and in vivo.

Free Research Field

泌尿器科腫瘍学